[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].

[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor]. Bull Cancer. 2021 Jan 30;: Authors: Rousseau A, Thieblemont C PMID: 33531153 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33531153?dopt=Abstract

Source: Bulletin du Cancer - January 30, 2021 Category: Cancer & Oncology Authors: Rousseau A, Thieblemont C Tags: Bull Cancer Source Type: research

More News: Cancer | Cancer & Oncology | Lymphoma | Science